Neuronetics (STIM) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Neuronetics (STIM) overview

Neuronetics (STIM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 149m and operating profit of USD -31.4m; the year-end share price was 1.38 USD and market capitalisation was USD 95.2m. Neuronetics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Neuronetics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 22.4mFY 2025
Share price1.38 USDFY 2025 year end
RevenueUSD 149mFY 2025
Operating profitUSD -31.4mFY 2025
Net earningsUSD -39.0mFY 2025
Market capitalisationUSD 95.2mFY 2025 year end

About Neuronetics

Neuronetics provides the NeuroStar Advanced Therapy System, an office-based, non-invasive treatment that uses transcranial magnetic stimulation to stimulate brain areas associated with mood. The system is cleared for specified adult and adolescent patients with major depressive disorder, as well as adults with obsessive-compulsive disorder and certain anxiety symptoms. Through its Greenbrook subsidiary, the company also operates mental healthcare treatment centers offering NeuroStar therapy and SPRAVATO.

Generate the Neuronetics report

Neuronetics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Neuronetics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Neuronetics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.